|

Recombinant oncolytic herpes simplex virus type 1 (R130) Clinical Trials

1 actively recruiting trial

No change since May 2026

Also known as: Oncolytic virus

Pipeline

Early 1: 1

Top Sponsors

  • Shanghai Yunying Medical Technology1

Indications

  • Kidney Cancer1
  • Carcinoma1
  • Brain Cancer1
  • Sarcoma1
  • Digestive Cancer1

Other1 trial

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.